CETACORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CETACORT (CETACORT).
Corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative properties; binds to glucocorticoid receptors, modulating gene transcription and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Hepatic via CYP3A4; undergoes first-pass metabolism. |
| Excretion | Renal: 95% as unchanged drug; biliary/fecal: <5% |
| Half-life | Terminal half-life: 3.5 hours; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.2 L/kg; distributes primarily into extracellular fluid |
| Bioavailability | Oral: 90% (fasting); Topical: 5-15% (varies with skin integrity and formulation) |
| Onset of Action | Oral: 1-2 hours; Intravenous: immediate; Topical: 2-4 hours |
| Duration of Action | Oral: 12-24 hours; Intravenous: 12-24 hours; Topical: 6-12 hours; clinical effect persists for duration exceeding serum levels due to slow receptor dissociation |
1-2 drops or 0.5-1 cm ribbon applied to affected eye(s) 3-4 times daily; for severe inflammation, every 1-2 hours initially. Ophthalmic suspension (0.5% prednisolone acetate) or ointment (0.25% prednisolone acetate).
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment due to negligible systemic absorption. |
| Pediatric use | Safety and efficacy not established; use same dosing as adults with caution, but limited to shortest duration necessary. |
| Geriatric use | No specific adjustment; use with caution due to increased risk of intraocular pressure elevation and cataract formation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CETACORT (CETACORT).
| Breastfeeding | Corticosteroids are excreted into breast milk in low amounts. M/P ratio for prednisolone is approximately 0.3; assume similar. At maternal doses up to 40 mg/day, infant dose is <10% of maternal weight-adjusted dose. Monitor infant for adrenal suppression if prolonged high-dose therapy. Consider delaying breastfeeding 4 hours after dose. |
| Teratogenic Risk | CETACORT is a corticosteroid with teratogenic potential. In the first trimester, increased risk of oral clefts (odds ratio approximately 3.4). Second/third trimester: risk of preterm birth, intrauterine growth restriction, and neonatal adrenal suppression. Avoid systemic use unless benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Untreated nasal infections (e.g., herpes simplex)"]
| Precautions | ["Nasal septal perforation","Growth retardation in children","Adrenal suppression with high doses","Increased risk of infections","Glaucoma/cataracts"] |
| Food/Dietary | No specific food interactions. Generally avoid excessive sodium intake if on long-term systemic therapy, but ophthalmic use has minimal systemic absorption. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of edema. Fetal monitoring: serial ultrasound for growth restriction, amniotic fluid volume, and Doppler studies if used in second half of pregnancy. Assess neonatal adrenal function postnatally if maternal use continued until delivery. |
| Fertility Effects | High-dose corticosteroids may disrupt menstrual cycle and ovulation, leading to reversible infertility. CETACORT at therapeutic doses is not associated with permanent fertility impairment. In males, may reduce sperm count and motility, usually reversible upon discontinuation. |
| CETACORT (prednisolone acetate) is a corticosteroid for ophthalmic use. Avoid prolonged use due to risk of increased intraocular pressure, cataract formation, and secondary infections. Taper dose if used >2 weeks. Monitor IOP in patients with glaucoma. Use with caution in corneal thinning disorders. |
| Patient Advice | Shake the suspension vigorously before each use. · Do not touch the dropper tip to the eye or any surface to avoid contamination. · Remove contact lenses before instillation and wait 15 minutes before reinserting. · Do not use for longer than prescribed; abrupt discontinuation can cause rebound inflammation. · Report any vision changes, eye pain, or discharge to your doctor immediately. |